Engineered stem cell therapy takes on Hard-to-Treat myeloma

NCT ID NCT05182073

Completed Disease control Sponsor: Fate Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This early-stage trial tested a new therapy called FT576, made from specially engineered stem cells that become cancer-fighting immune cells. It was given alone or with another drug, daratumumab, to 31 people with multiple myeloma that had returned or stopped responding to prior treatments. The goal was to find a safe dose and see if the therapy could shrink the cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: FT576 (engineered immune cells from stem cells) and daratumumab (a targeted antibody)
What this could lead to: If successful, this could point toward a new treatment option for multiple myeloma that has stopped responding to other therapies.
What could go wrong: This is an early Phase 1 trial with only 31 participants, so safety and effectiveness are not yet proven. The treatment may cause side effects or fail to control the cancer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma plasma cell neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA MYELOMA

Contacts and locations

Locations

City of Hope

Duarte, California, 91010, United States
Indiana University

Indianapolis, Indiana, 46202, United States
Levine Cancer Institute

Charlotte, North Carolina, 28204, United States
Medical College of Wisconsin

Milwaukee, Wisconsin, 53226, United States
Medical Oncology Hematology Consultants

Newark, Delaware, 19713, United States
Oncology Hematology Care, Inc

Cincinnati, Ohio, 45226, United States
Roswell Park

Buffalo, New York, 14263, United States
Scri-Cbci

Denver, Colorado, 80218, United States
Tennessee Oncology - Nashville

Nashville, Tennessee, 37203, United States
Texas Oncology-Medical City Dallas

Dallas, Texas, 75230, United States
University of Alabama at Birmingham

Birmingham, Alabama, 35205, United States
University of Minnesota

Saint Paul, Minnesota, 55108, United States
Virginia Oncology Associates

Norfolk, Virginia, 23502, United States
Washington University

St Louis, Missouri, 63130, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.